# TABLE OF CONTENTS

- Message from the President 4
- Research 6
- Global Outreach 8
- Empowering Patients 10
- Development 12
- Summary Financial Information 13
Dear Friends,

Once again, it’s my pleasure to share with you all the advances and achievements the IMF has accomplished! Needless to say, this past year has been very busy and most importantly, very productive in our four key areas: research, education, support, and advocacy.

In November 2016, you may have read that the Black Swan Research Initiative® launched its first large-scale screening to identify and treat the precursors of myeloma before the disease develops. Over the past year, the study iStopMM® (Iceland Screens, Treats or Prevents Multiple Myeloma) has been examining blood samples of patients in Iceland. More than 140,000 adults in Iceland over the age of 40 were invited to be screened to determine if they have the earliest signs of myeloma. Excited about this, 77,777 Icelanders elected to participate in this groundbreaking project!

We’ve continued to go to Iceland working closely with Dr. Sigurdur Kristinsson and his team. Dr. Kristinsson estimates that 4% of those screened will have MGUS (monoclonal gammopathy of undetermined significance). The accrual is happening quickly and will end up with over 4,000 MGUS patients. This is the largest population-based screening study for myeloma and its earlier disease precursors that has ever been attempted! Needless to say, I’m very proud of Dr. Durie and Dr. Kristinsson for their vision, passion, and tenacity to get this project going; and to all the people in Iceland who are participating in this incredible study! Stay tuned for more updates about iStopMM as we learn which patients will benefit most from early intervention, as well as those identified with high-risk smoldering myeloma.

In June we traveled to Madrid, Spain, for the annual meeting of the International Myeloma Working Group (IMWG) meeting. This keystone meeting is held just prior to the annual EHA (European Hematology Association) meeting. About 100 IMWG members attended and the Summit was co-chaired by Drs. Brian Durie, Philippe Moreau, S. Vincent Rajkumar and Jesús F. San Miguel. Important topics included Frontline Therapy for Myeloma, Role of MRD Assessment, Drug Access, and the Costs of Myeloma Care, to name a few. A highlight of the Summit was the Robert A. Kyle Lifetime Achievement Award that was presented to Dr. Paul Richardson of the Dana-Farber Cancer Institute. Another highlight was the annual meeting of GMAN (Global Myeloma Action Network). Thirty-four members gathered from around the world to attend this very active and productive meeting.

The IMF also was very busy on the home front, conducting 4 Patient & Family Seminars and 12 Regional Community Workshops. The Patient & Family Seminars are a half day on Friday and a full day on Saturday, and the Regional Community Workshops are a half day. We’re very grateful to the outstanding faculty, who donate their time by participating at these meetings.

Our Support Group Team led by Robin Tuohy along with Nancy Bruno, Kelly Cox, and Ann Pacowta, crisscrosses the country year-round. They visit Support Groups to ensure these groups have what they need and are enabled to overcome any challenges. I’m very proud to note that we have 150 Support Groups nationwide, and we’re honored to endorse them!

One of the biggest challenges we face is ensuring that patients have access to the drugs they need, when they need them. I don’t have to tell you how expensive myeloma is… No one should have to choose between food or medicine. But in this great country of ours, they do. I’m extremely grateful to our outstanding Advocacy Team, led by Robin Levy, Senior Director of Public Policy & Advocacy. She began her career in the Executive Branch of the federal government working in the White House Counsel’s office during the Clinton Administration. She is joined by her amazing team of Ray Wezik, Danielle Doheny, and Kelley Sidorowicz; together, they are working for you to ensure you have access to treatment. Most importantly, though, we are grateful to you – IMF donors and volunteer advocates.

I urge you to get involved in any of these incredible programs: research, education, support, and advocacy. After all, we are One Myeloma Nation!

Sincerely yours,

Susie Durie
President & CEO
IMF Board of Directors

Susie Durie  
Founder, President, and CEO  
of International Myeloma Foundation  
Los Angeles, CA

Brian G. M. Durie, MD  
Chairman of the Board  
Professor of Medicine  
Hematologist/Oncologist  
Los Angeles, CA

Christine Battistini  
President of International Myeloma  
Foundation Latin America and Instituto  
Espaço de Vida  
São Paulo, Brazil

Yelak Biru  
Director, Business Intelligence and  
Advanced Analytics, Walmart  
Bentonville, Arkansas

Mario Boccadore, MD  
Professor of Medicine,  
University of Torino  
Torino, Italy

Benson Klein, JD  
Principal Member, Ward & Klein  
Rockville, MD

Andrew Kuzneski, III  
President, Kuzneski Financial Group  
President, Greyhawk Capital  
Indiana, PA

Robert A. Kyle, MD  
Professor of Medicine and  
Laboratory Medicine and Pathology  
Mayo Clinic – Rochester, MN

Professor Heinz Ludwig, MD  
Director of Department of Medicine  
and Medical Oncology  
Wilhelminespital der Stadt Wien  
Vienna, Austria

Edith P. Mitchell, MD  
Clinical Professor of Medicine,  
Jefferson Medical College  
Brigadier General, National Guard  
Philadelphia, PA

Charles Newman, MS  
Chairman of the Board, ContentOro Founder,  
Protectors of Equality in Government  
Board Member, Bank of Ann Arbor  
Ann Arbor, MI

S. Vincent Rajkumar, MD  
Professor of Medicine, Mayo Clinic  
Rochester, MN

Matthew Robinson, MBA  
IMF Board Member - Los Angeles, CA

E. Michael D. Scott, CPA, JD  
Healthcare Strategist/Executive Rebel,  
Calcium – Philadelphia, PA

Susie Durie  
Founder, President, and CEO  
of International Myeloma Foundation  
Los Angeles, CA

Jennifer Scarne  
Chief Financial Officer / Chief Operating Officer

Diane Moran  
Senior Vice President, Strategic Planning

Lisa Paik  
Senior Vice President, Clinical Education & Research Initiatives

Daniel Navid  
Senior Vice President, Global Affairs

Joseph Mikhael, MD  
Chief Medical Officer

Susie Durie  
Founder, President, and CEO  
of International Myeloma Foundation  
Los Angeles, CA

Jennifer Scarne  
Chief Financial Officer / Chief Operating Officer

Diane Moran  
Senior Vice President, Strategic Planning

Lisa Paik  
Senior Vice President, Clinical Education & Research Initiatives

Daniel Navid  
Senior Vice President, Global Affairs

Joseph Mikhael, MD  
Chief Medical Officer

IMF Executive Team

Sevag Abajian  
Database Manager

Peter Anton  
Senior Director, Marketing

Betty Arevalo  
Inventory Control Manager

Suzanne Battaglia  
Director, Member Events

Debbie Birns  
Medical Editor

Nancy Bruno  
Southeast Regional Director,  
Support Groups

Kelly Cox  
Director, Support Groups &  
Regional Community Workshops

Elaine DeLasho  
Administrative Assistant,  
Strategic Planning

Danielle Doheny  
Director, Public Policy & Advocacy

Nadia Elkebir  
Senior Global Director of Advocacy,  
Europe and the Middle East /  
GMAN Executive Director

Heather Fishman  
Donor Relations

Jon Fitzpatrick  
Support Group Coordinator

Carmen Greene  
Meeting Coordinator

Abigail Guzman  
Assistant Meeting Planner

Paul Hewitt  
InfoLine Coordinator

Kevin Huynh  
Web Specialist

Marya Kazakova  
Editor-in-Chief, Publications

Ilana Kenville  
Member Events Associate

Missy Klepetar  
InfoLine Coordinator

Sapna Kumar  
Communications Associate

Xuan Lam  
Medical Affairs Assistant

Phil Lange  
Accountant

Robin Roland Levy  
Senior Director,  
Public Policy & Advocacy

Amirah Limayo  
Research Project Coordinator

Randi Lovett  
Vice President,  
Communications & Development

Jim Needham  
Publication Design

Anne Pacowta  
Florida Regional Director,  
Support Groups

Selma Plascencia  
Director of Operations

Annabel Reardon  
Director of Meetings & Events

Joy Riznikove  
Donor Relations

Miko Santos  
Web Producer

Kelley Sidorowicz  
Director, Public Policy & Advocacy

Brando Sordoni  
Accounting & Distribution

Rafi Stephan  
Assistant to President

Robin Tuohy  
Senior Director, Support Groups

Judy Webb  
InfoLine Coordinator

Jonathan Weitz  
Donor Relations

Raymond L. Wezik, JD  
Director, Public Policy & Advocacy

IMF Staff

Sevag Abajian  
Database Manager

Peter Anton  
Senior Director, Marketing

Betty Arevalo  
Inventory Control Manager

Suzanne Battaglia  
Director, Member Events

Debbie Birns  
Medical Editor

Nancy Bruno  
Southeast Regional Director,  
Support Groups

Kelly Cox  
Director, Support Groups &  
Regional Community Workshops

Elaine DeLasho  
Administrative Assistant,  
Strategic Planning

Danielle Doheny  
Director, Public Policy & Advocacy

Nadia Elkebir  
Senior Global Director of Advocacy,  
Europe and the Middle East /  
GMAN Executive Director

Heather Fishman  
Donor Relations

Jon Fitzpatrick  
Support Group Coordinator

Carmen Greene  
Meeting Coordinator

Abigail Guzman  
Assistant Meeting Planner

Paul Hewitt  
InfoLine Coordinator

Kevin Huynh  
Web Specialist

Marya Kazakova  
Editor-in-Chief, Publications

Ilana Kenville  
Member Events Associate

Missy Klepetar  
InfoLine Coordinator

Sapna Kumar  
Communications Associate

Xuan Lam  
Medical Affairs Assistant

Phil Lange  
Accountant

Robin Roland Levy  
Senior Director,  
Public Policy & Advocacy

Amirah Limayo  
Research Project Coordinator

Randi Lovett  
Vice President,  
Communications & Development

Jim Needham  
Publication Design

Anne Pacowta  
Florida Regional Director,  
Support Groups

Selma Plascencia  
Director of Operations

Annabel Reardon  
Director of Meetings & Events

Joy Riznikove  
Donor Relations

Miko Santos  
Web Producer

Kelley Sidorowicz  
Director, Public Policy & Advocacy

Brando Sordoni  
Accounting & Distribution

Rafi Stephan  
Assistant to President

Robin Tuohy  
Senior Director, Support Groups

Judy Webb  
InfoLine Coordinator

Jonathan Weitz  
Donor Relations

Raymond L. Wezik, JD  
Director, Public Policy & Advocacy

Based in North Hollywood, California, the International Myeloma Foundation gathers yearly for an annual staff retreat.
Black Swan Research Initiative
The International Myeloma Foundation’s signature research project

Made up of an exciting team of multinational researchers, the Black Swan Research Initiative® experienced a pivotal year in 2017:

• The IMF celebrated the one-year anniversary of the iStopMM® project, which stands for Iceland Screens, Treats, or Prevents Multiple Myeloma. The largest myeloma-related study of its kind under the direction of Dr. Sigurdur Kristinsson (the University of Iceland), the iStopMM project has had an unprecedented response from the Icelandic people. Approximately 140,000 individuals over 40 years of age were asked to participate and be screened for possible monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or active MM; thus far 77,777 have signed up. These participants have agreed to be tested as well as randomized to be more rigorously tested and/or possibly treated with interventional myeloma therapy.

Because much of the Icelandic population has already undergone genetic coding, iStopMM researchers will be able to use this genetic data to look for linkages to family gene patterns in those with MGUS. In addition, a questionnaire asks participants about family history and exposure history to see what conditions may lead to the disease. The chances are excellent that answers will be found to help the BSRI team understand the biology of why people develop MGUS and how it can be prevented.

• The U.S.-based ASCENT trial (Aggressive Smoldering Cure Evaluating Novel Therapies) is headed by Dr. Shaji Kumar of the Mayo Clinic (Rochester, MN) and uses a combination of carfilzomib + lenalidomide + dexamethasone + daratumumab in an attempt to cure patients with high-risk smoldering multiple myeloma (HR-SMM). The trial, along with the CESAR and iStopMM clinical trials, is one of three BSRI-funded “Cure” trials. All enrolled patients will receive a reduced dose of carfilzomib + lenalidomide + daratumumab for one year of maintenance. At this point, a 100 percent level of minimal residual disease (MRD) negativity is highly likely, said Dr. Brian G.M. Durie. MRD testing will be done at diagnosis and during therapy, allowing intensive tracking of the disease in patients. MRD testing can detect even a single myeloma cell surviving among one million bone marrow cells. The number of cycles of therapy will be determined by the individual patient’s response.

The ASCENT trial will open for accrual in 2018 at 12 IMF Consortium sites.
• Interim data presented at the 2017 Annual Meeting of the American Society of Hematology from the single-arm, phase II CESAR trial demonstrated a high rate of complete responses (CRs) in patients with high-risk smoldering myeloma. Patients were given induction therapy with carfilzomib + lenalidomide + dexamethasone followed by high-dose therapy and autologous stem cell transplantation (HDT-ASCT), consolidation therapy and then maintenance therapy with lenalidomide + dexamethasone.

The CESAR trial, based in Spain and led by Dr. María-Victoria Mateos of University Hospital of Salamanca (Spain), is, along with the ASCENT and iStopMM clinical trials, one of three BSRI-funded “Cure” trials. Although longer follow-up is required, this curative strategy for high-risk SMM is encouraging.

Results of the CESAR trial were published in the journal Blood.

International Myeloma Working Group

The International Myeloma Foundation’s collaborative working group of more than 200 myeloma experts

In 2017, the IMF’s International Myeloma Working Group (founded in 2001) published “Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study” by Dr. Sha ji Kumar and hosted lively teleconferences, interacting with patient and caregiver communities.

The eighth annual IMF IMWG Summit was held in Madrid from June 19–21, 2017. It included breakout sessions during which participants provided action plans on the following: drug access and the cost of myeloma care, bone scanning and imaging, immunotherapy, studies on smoldering myeloma, and a discussion of how to treat high-risk myeloma.

In addition, patients, caregivers, and doctors from around the world gleaned insights on the latest myeloma research and treatment when they tuned into the livestream broadcast from the Summit on June 21. Other highlights from the Summit included the presentation of the IMF’s 14th Annual Robert A. Kyle Lifetime Achievement Award to Dr. Paul G. Richardson on June 20, 2017. This award honors an individual whose body of work has made significant contributions to myeloma research and patient care.

IMWG Publications


The International Myeloma Foundation (IMF) presented its 2017 Research Grant awards at a ceremony held during the 58th annual meeting of the American Society of Hematology (ASH), December 2016 in San Diego, California.

**Senior Grant Recipients**
Senior Research Grant projects are funded at $80,000.

**Myeloma Master Class**
The Myeloma Master Class is an intensive educational course the IMF began six years ago to train clinicians who specialize in myeloma. The fifth annual Master Class, held in August 2017 in Los Angeles, welcomed seven young Chinese hematologists from leading myeloma centers throughout China.

In addition to classroom learning, the doctors took part in the IMF Los Angeles Patient & Family Seminar, where they participated in individual patient consultations alongside Dr. Brian G.M. Durie (Hematologist/Oncologist at Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, Los Angeles, and IMF Chairman of the Board).

The Master Class featured several days of interactive lectures and discussions on the full range of modern myeloma diagnosis and treatment with leading myeloma specialists Dr. Brian G.M. Durie, Dr. S. Vincent Rajkumar (Mayo Clinic, Rochester, MN), Dr. Jonathan Kaufman (Winship Cancer Institute, Emory University, Atlanta), Dr. Thomas G. Martin (Helen Diller Comprehensive Cancer Center, UCSF, San Francisco), Dr. Joseph Mikhail (Mayo Clinic, Scottsdale, AZ), and Dr. Robert Vescio (Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, Los Angeles).

The Master Class provided not only a valuable educational opportunity, but a chance for these young Chinese doctors to develop friendships and professional contacts. Master Class alumni are becoming leading figures in the myeloma community in China, which will no doubt lead to improved patient support and care.

**GLOBAL OUTREACH**

2017 Brian D. Novis Research Grant Awards

**GLOBAL OUTREACH**

**2017 Brian D. Novis Research Grant Awards**

These Chinese hematologists were presented with their certificates at the close of the Myeloma Master Class.

**Global Outreach:**

**Djordje Atanackovic, MD** | Huntsman Cancer Institute – Salt Lake City, UT

Anti-CD229 chimeric antigen receptor T cells for the treatment of multiple myeloma

**Felipe Prosper, MD** | Foundation for Applied Medical Research (FIMA) – Pamplona, Navarra, Spain

Deciphering the role of eRNAs in the pathogenesis of multiple myeloma

**Karin Vanderkerken, PhD** | Vrije Universiteit Brussel – Brussels, Belgium

Targeting residual, dormant cancer cells in myeloma: a new approach

**Global Outreach:**

**Neelam Bhardwaj, PhD** | Huntsman Cancer Institute – Salt Lake City, UT

Generation and validation of a monoclonal antibody against VISTA for the immunomodulatory therapy of multiple myeloma

**Arnold Bolomsky, DI (FH) Dr.** | Wilhelminen Cancer Research Institute – Vienna, Austria

Targeting of BMI-1 as novel treatment option in multiple myeloma: Examination of PTC-028 as putative anti-myeloma drug in vitro and in vivo

**Jesús Delgado-Calle, PhD** | Indiana University School of Medicine – Indianapolis, IN

Bone/bone marrow-targeted inhibition of Notch signaling in combination with glucocorticoid therapy as a novel approach to treat multiple myeloma

**Geoffrey M. Matthews, PhD** | Dana-Farber Cancer Institute – Boston, MA

Treating myeloma through inducing degradation of BET bromodomain proteins

**Alessandra Romano, MD, PhD** | Ospedale San Raffaele – Milano, Italy

Exploiting IDO1-GCN2-p62 axis in MM microenvironment to trigger myeloid-derived suppressor cells in multiple myeloma
Global Myeloma Action Network

GMAN brings together advocacy leaders in myeloma and blood cancers to improve the lives of patients around the world.

Susie Durie – President, Founder, and CEO of the IMF – kicked off the GMAN meeting in fiscal year 2017, at the Annual Meeting of the American Society of Hematology in San Diego in early December 2016. Participants were thanked with a warm welcome for their willingness to work together to benefit patients. At this meeting, GMAN members had a chance to meet with industry physicians from the U.S.

The GMAN Summit, a large-scale meeting, took place in June 2017 at the IMF’s International Myeloma Working Group (IMWG) Summit in Madrid, Spain. This GMAN encounter garnered a great level of participation, drawing 35 individuals representing 25 countries around the world. The Summit included presentations and breakout sessions. Dr. Jean-Luc Harousseau (University of Nantes, Nantes, France) presented on “The Cost of New Myeloma Treatments.” Dr. Durhane Wong-Rieger (President, Canadian Organization of Rare Disorders) discussed “Real World Advocacy: Advancing Research and Access,” and led a training session on “Advancing Public Policies That Support Research, Improve Access to Treatments, and Yield Real Results.” Dr. Rafat Abonour (Simon Cancer Center, Indiana University, Bloomington, Indiana) led a breakout session on what to do if access to novel therapies is unavailable, a topic that resonated with many GMAN representatives of countries where myeloma treatment options are limited. The Summit agenda also included a session on navigating clinical trials for access to novel therapies and presentations by several representatives from member organizations in Asia, Europe, Latin America, and North America. GMAN remains a unique global myeloma advocacy initiative, and its annual Summit fosters an environment that supports existing relationships and develops new ones.

Educational Outreach in Europe

The IMF continued to strengthen its international relationships with patients, families, and advocacy groups abroad in 2017 with educational meetings in 15 European countries, which were attended by more than 3,200 people in the international myeloma community. By collaborating with doctors in each country, the IMF works to provide the most updated myeloma research and treatment information to patients in their own languages.
The International Myeloma Foundation (IMF) Nurse Leadership Board® (NLB) is a professional partnership representing nurse experts from leading medical centers caring for myeloma patients. Throughout fiscal year 2017, NLB members led education sessions at IMF Patient & Family Seminars and Regional Community Workshops, accompanied support group leaders to the 2016 Annual Meeting of the American Society of Hematology (ASH), and addressed the IMF’s 2017 Support Group Leaders Summit. The NLB contributed to IMF publications and spoke on teleconferences in the IMF’s popular “Living Well with Myeloma” series.

The NLB’s 12th annual meeting was held in Los Angeles in August 2017. During this meeting, the NLB heard updates from IMF Chairman Dr. Brian G. M. Durie on the latest Black Swan Research Initiative® studies, reviewed the results of a survey that assessed the unmet needs of myeloma patients, and participated in breakout sessions. Of note, the NLB began testing a Myeloma Nurse app to leverage broader dissemination of NLB resources, manage events, and share information.

In April, at the 2017 Oncology Nursing Society annual conference in Denver, the NLB hosted a CNE-accredited satellite symposium entitled “Case Studies in Multiple Myeloma: Best Practices in Patient Care and Symptom Management.” The event was co-chaired by Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN® (Taussig Cancer Institute–Cleveland Clinic, Cleveland, OH) and Joseph Tariman, PhD, RN, ANP-BC, FAAN (DePaul University–Chicago, IL).

In October, the *Clinical Journal of Oncology Nursing* published *Multiple Myeloma*, authored by the International Myeloma Foundation’s Nurse Leadership Board. This publication provides downloadable PDFs of research-based articles on myeloma symptoms and complications and their management.

Also, this past fiscal year, the NLB’s Dr. Joseph Tariman was inducted as a Fellow to the American Academy of Nursing. The IMF congratulates all of the NLB for their tremendous contributions to myeloma education.
IMF Advocacy Navigates Changes in Healthcare

In fiscal year 2017, the IMF Advocacy Team:

- Followed the 21st Century Cures Act, a law passed with bipartisan backing and signed by President Barack Obama. This law authorizes cancer research funding and funds for the U.S. Food and Drug Administration (FDA) to streamline drug and device approval processes. In particular, it authorizes nearly $5 billion for the National Institutes of Health Innovation Account for more than 10 years with $300 million allocated to the National Cancer Institute. The IMF Advocacy team informed the public about this Act and bolstered activism related to it.

- Continued to monitor oral parity legislation at both the federal and state level which ensures insurance benefits are meeting up properly with healthcare innovations. At the state level, the IMF Advocacy Team continued to advocate for legislation in North Carolina, Tennessee, and Michigan. In April, oral parity became law in Arkansas. As a result, 43 states and the District of Columbia now have similar laws to increase access to life-saving drugs. At the federal level, the IMF and the Patients Equal Access Coalition (PEAC) thank Congressman Leonard Lance (R-NJ-7th district) and Brian Higgins (D-NY-26th district) for introducing the Cancer Drug Parity Act of 2017.

- Cultivated legislative solutions to reexamine Medicare policies, specifically specialty tiers.

- Advanced helpful measures for U.S. veterans with myeloma, including legislation that would affect Blue Water Veterans who served in the Navy and the Coast Guard off Vietnam’s shore during the Vietnam War. The IMF Advocacy team also joined with advocates from other disease groups and researchers nationwide to save the Congressionally Directed Medical Research Program (CDMRP). The CDMRP funds high-impact and risky research that often results in breakthrough treatments and technologies. CDMRP’s research efforts to study cancer in service members was under attack by a provision in the National Defense Authorization Act. In part to IMF Advocacy’s efforts, the program was saved.

If you have any questions about specific legislation that could affect the myeloma community, contact the IMF Advocacy Team at advocacy@myeloma.org.
There Is No Such Thing As a Drop in the Bucket – Everything Counts!

After losing his mother Carole Newman to multiple myeloma, Jeffrey Newman was compelled to take action. Carole’s battle with the disease lasted five years. Carole lived independently in New York City during most of her life, and Jeffrey’s sister Cynthia along with his brother Bill provided the care his mother needed during her illness. During the final four months of life, the family moved Carole closer to Jeffrey’s brother’s home in Massachusetts. Jeffrey commented that, surrounded by family, his mother maintained her remarkable poise until the very end.

Not only affected by the loss of his mother, Jeffrey also has a close friend who has been living with myeloma for several years. Jeffrey felt a strong drive to “fight back” and decided to take action. His friend then introduced him to the International Myeloma Foundation (IMF).

The IMF’s signature research program, the Black Swan Research Initiative® (BSRI), which aims to develop a definitive cure for myeloma, piqued Jeffrey’s interest. Led by a team of global myeloma experts, the BSRI coordinates and supports more than 40 research projects around the world.

Jeffrey was especially excited to hear about how the BSRI team has overcome the first obstacle to finding a cure for myeloma by developing a very sensitive, reliable, standardized, and affordable test to detect minimal residual disease (MRD). The BSRI’s Next Generation Flow (NGF) flow cytometry technique, paired with a specialized software package, can quantify and characterize even one single myeloma cell that may remain after a patient is in complete response (CR).

Jeffrey was drawn to this aspect of BSRI research because it makes a tangible contribution to the field of myeloma in very specific way. The family’s fund, the Jerome A. and Estelle R. Newman Assistance Fund – as well as Jeffrey individually – contribute to BSRI research. The hope is that this simple blood test is truly the next step in detecting and preventing the progression of disease in patients with myeloma. “It gives me great satisfaction to know that there is real light in the battle against this insidious disease and that our contributions will have a real impact. I encourage others – if they have the means – to get involved in any way they can,” said Jeffrey. “Some people feel that fighting a disease is such an enormous task, and ask themselves, ‘What can I do? I mean, anything I can give is only like a drop in the bucket.’ But everything counts, especially when it comes to research.”

Jeffrey hopes that you, too, will connect with the IMF to learn how to give in a targeted way that speaks to you. And most of all, he honors the memory of his mother Carole whom he will always value as “a respectful, decent, loving person who endowed me with an appreciation for sports and art and a classy way of going. She lived her life in an unpretentious way and would most appreciate what we are doing in her honor.”

The entire IMF team is grateful to Jeffrey and the Newman family for all they do.

If you wish to discuss supporting the IMF in a way that works best for you, please contact Randi Lovett at rlovett@myeloma.org or 818.487.7455.
### INTERNATIONAL MYELOMA FOUNDATION

**Statement of Financial Position**
**September 30, 2017**

#### Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,871,136</td>
</tr>
<tr>
<td>Restricted cash, gift annuity investment</td>
<td>8,261</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>5,315,517</td>
</tr>
<tr>
<td>Contributions, program grants, and other receivables</td>
<td>10,184,182</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>894,936</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>878,776</td>
</tr>
<tr>
<td>Intangible assets, net</td>
<td>100,757</td>
</tr>
</tbody>
</table>

**TOTAL ASSETS** $19,253,565

#### Liabilities and Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$1,731,656</td>
</tr>
<tr>
<td>Deferred program and educational grants</td>
<td>9,434,342</td>
</tr>
<tr>
<td>Gift annuity obligation</td>
<td>5,354</td>
</tr>
</tbody>
</table>

**TOTAL LIABILITIES** $11,171,352

**NET ASSETS**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$7,929,306</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>152,907</td>
</tr>
</tbody>
</table>

**TOTAL NET ASSETS** $8,082,213

**TOTAL LIABILITIES AND NET ASSETS** $19,253,565

For a copy of our complete audited financial statements, please contact the IMF office.
INTERNATIONAL MYELOMA FOUNDATION

Statement of Activities for the Year Ended September 30, 2017

### Revenues and Support

<table>
<thead>
<tr>
<th>Description</th>
<th>UNRESTRICTED</th>
<th>TEMPORARILY RESTRICTED</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Educational and program grants</td>
<td>$7,794,976</td>
<td>$5,144,611</td>
<td>$12,939,587</td>
</tr>
<tr>
<td>General contributions</td>
<td>869,654</td>
<td>179,124</td>
<td>1,048,778</td>
</tr>
<tr>
<td>Fundraising programs</td>
<td>325,540</td>
<td>3,777</td>
<td>329,317</td>
</tr>
<tr>
<td>Seminar fees and support group income</td>
<td>59,198</td>
<td>-</td>
<td>59,198</td>
</tr>
<tr>
<td>Fundraising events, net of direct benefit to donors</td>
<td>337,523</td>
<td>627,074</td>
<td>964,597</td>
</tr>
<tr>
<td>Realized and unrealized gains, net</td>
<td>177,284</td>
<td>-</td>
<td>177,284</td>
</tr>
<tr>
<td>Investment income</td>
<td>169,842</td>
<td>255</td>
<td>170,097</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>8,392,994</td>
<td>(8,392,994)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total Revenues and Support</strong></td>
<td>$18,127,011</td>
<td>(2,438,153)</td>
<td>$15,688,858</td>
</tr>
</tbody>
</table>

### Functional Expenses

<table>
<thead>
<tr>
<th>Description</th>
<th>UNRESTRICTED</th>
<th>TEMPORARILY RESTRICTED</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>$14,392,302</td>
<td>$-</td>
<td>$14,392,302</td>
</tr>
<tr>
<td>General supporting services</td>
<td>647,853</td>
<td>-</td>
<td>647,853</td>
</tr>
<tr>
<td>Fundraising</td>
<td>984,967</td>
<td>-</td>
<td>984,967</td>
</tr>
<tr>
<td><strong>Total Functional Expenses</strong></td>
<td>$16,025,122</td>
<td>-</td>
<td>$16,025,122</td>
</tr>
</tbody>
</table>

### Change in Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>UNRESTRICTED</th>
<th>TEMPORARILY RESTRICTED</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in Net Assets</td>
<td>$2,101,889</td>
<td>$ (2,438,153)</td>
<td>$ (336,264)</td>
</tr>
<tr>
<td>NET ASSETS – Beginning of year</td>
<td>5,827,417</td>
<td>2,591,060</td>
<td>8,418,477</td>
</tr>
<tr>
<td>NET ASSETS – End of year</td>
<td>$7,929,306</td>
<td>$152,907</td>
<td>$8,082,213</td>
</tr>
</tbody>
</table>

### Revenue Breakdown*

- Research: 49%
- Educational and Program Grants – General: 36%
- General Contributions: 13%
- All other: 2%

### Expense Breakdown

- Research and Program Expenses: 90%
- Fundraising: 6%
- General Support Services: 4%

* Percentages based upon detailed final trial balance.
# INTERNATIONAL MYELOMA FOUNDATION

## Statement of Functional Expenses

for the Year Ended September 30, 2017

### Breakdown of Expenses by Program

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>TOTAL EXPENSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$ 6,993,161</td>
</tr>
<tr>
<td>Education &amp; Awareness</td>
<td>1,816,514</td>
</tr>
<tr>
<td>Patient &amp; Family Seminars</td>
<td>1,194,623</td>
</tr>
<tr>
<td>International</td>
<td>1,045,878</td>
</tr>
<tr>
<td>Support Groups</td>
<td>823,684</td>
</tr>
<tr>
<td>Nurse</td>
<td>633,083</td>
</tr>
<tr>
<td>Advocacy</td>
<td>556,308</td>
</tr>
<tr>
<td>Myeloma Today</td>
<td>358,550</td>
</tr>
<tr>
<td>InfoLine</td>
<td>344,538</td>
</tr>
<tr>
<td>Website</td>
<td>304,974</td>
</tr>
<tr>
<td>Clinical Meetings</td>
<td>212,392</td>
</tr>
<tr>
<td>Information Mailings</td>
<td>108,597</td>
</tr>
</tbody>
</table>

| Total Program Expenses   | $ 14,392,302   |
| General Supporting Expenses | $ 647,853    |
| Fundraising Expenses      | 984,967        |

| Total Expenses            | $ 16,025,122   |

For a copy of our complete audited financial statements, please contact the IMF office.
Improving Lives Finding the Cure®

International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607 USA

800.452.CURE (2873)
toll-free in U.S. and Canada

818.487.7455
worldwide

ThelMF@myeloma.org

myeloma.org